Cellectar Biosciences Inc (CLRB)

[Crusader]

Recent CNBC News Mentioning CLRB:

https://www.cnbc.com/2017/08/09/pr-newswire-latest-rd-success-fda-approvals-and-significant-advances-in-clinical-trials-boosting-biotech-sector.html

"...Collector Biosciences Inc. (NASDAQ: CLRB) came to a close up 11.39% on Tuesday at $1.76 with a volume of over 5.9 million shares traded by the market close. The company recently announced its lead PDC compound, CLR 131 has achieved a median overall survival of 22.5 months to date after a single dose infusion of 12.5 mCi/m2 in patients with multiple myeloma. Patients in the first cohort of the company's Phase 1 clinical trial had an average of 5.8 prior lines of treatment and therefore were considered to be heavily pretreated. It is important to note that the trial remains ongoing, and the overall survival could continue to increase over time. While there have been no head-to-head studies, for comparison, this ongoing overall survival length from the company's Phase 1 clinical trial exceeds historic published outcomes of currently marketed second and third line treatment modalities for multiple myeloma...."